SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Northwest Bioth...
September 23 2015 - 3:31PM
The securities litigation law firm of Brower Piven, A Professional
Corporation, announces that a class action lawsuit has been
commenced in the United States District Court for the District of
Maryland on behalf of purchasers of Northwest Biotherapeutics, Inc.
(Nasdaq:NWBO) (“Northwest Biotherapeutics” or the “Company”)
securities during the period between March 8, 2013 and August 20,
2015, inclusive (the “Class Period”). Investors who wish to
become proactively involved in the litigation have until October
26, 2015 to seek appointment as lead plaintiff.
Northwest Biotherapeutics is headquartered in
Maryland. Brower Piven is the only firm headquartered in
Maryland with a practice dedicated primarily to shareholder class
action litigation.
If you have suffered a loss from investment in
Northwest Biotherapeutics securities purchased on or after March 8,
2013 and held through the revelation of negative information during
and/or at the end of the Class Period, as described below, and
would like to learn more about this lawsuit and your ability to
participate as a lead plaintiff, without cost or obligation to you,
please visit our website at
http://www.browerpiven.com/currentsecuritiescases.html. You
may also request more information by contacting Brower Piven either
by email at hoffman@browerpiven.com or by telephone at (410)
415-6616. No class has yet been certified in the above
action. Members of the Class will be represented by the lead
plaintiff and counsel chosen by the lead plaintiff.
If you wish to choose counsel to represent you
and the Class, you must apply to be appointed lead plaintiff and be
selected by the Court. The lead plaintiff will direct the
litigation and participate in important decisions including whether
to accept a settlement for the Class in the action. The lead
plaintiff will be selected from among applicants claiming the
largest loss from investment in Company securities during the Class
Period. Brower Piven also encourages anyone with information
regarding the Company’s conduct during the period in question to
contact the firm, including whistleblowers, former employees,
shareholders and others.
The Complaint accuses the defendants of
violations of the Securities Exchange Act of 1934 by virtue of the
defendants’ failure to disclose during the Class Period that the
Company’s claims regarding positive results from its DCVax-Direct
Trial were based on preliminary and unconfirmed trial results that
had not been reviewed or analyzed by the hospitals conducting the
trials and that the Company was the subject of an aggressive
stock promotion campaign which included promoters using fictitious
identities and false credentials, and that German regulators
required additional information to consider whether to allow the
DCVax-L Trial to continue uninterrupted.
According to the Complaint, following: (1) a
June 19, 2014 report from, The Street.com that MD
Anderson Cancer Center had issued a stern rebuke to Northwest Bio
for promoting, unjustified claims about results from the ongoing
clinical trial of DCVax-Direct; (2) a July 7, 2014, report
published on SeekingAlpha.com stating that the Company
was the subject of a massive promotional campaign where in some
cases, authors have used fictitious identities and fake credentials
when they are actually paid writers; (3) an August 21,
2015 pre-market news story revealing that the Company’s Phase 3
DCVax-L brain cancer treatment clinical trial in Germany was
temporarily suspended; and (4) a Company announcement that same day
that new screening of patient candidates for the trial had been
temporarily suspended while the Company submitted certain
information from the trial for regulatory review, the value of
Northwest Biotherapeutics shares declined significantly.
Attorneys at Brower Piven have extensive
experience in litigating securities and other class action cases
and have been advocating for the rights of shareholders since the
1980s. If you choose to retain counsel, you may retain Brower
Piven without financial obligation or cost to you, or you may
retain other counsel of your choice. You need take no action
at this time to be a member of the class.
CONTACT:
Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
hoffman@browerpiven.com
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Apr 2023 to Apr 2024